Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 77-89 http://medscipublisher.com/index.php/cge 89 Welsbie D., Xu J., Chen Y., Borsu L., Scher H., Rosen N., and Sawyers C., 2009, Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer, Cancer Research, 69(3): 958-966. Urbanucci A., Barfeld S., Kytöla V., Itkonen H., Coleman I., Vodák D., Sjöblom L., Sheng X., Tolonen T., Minner S., Burdelski C., Kivinummi K., Kohvakka A., Kregel S., Takhar M., Alshalalfa M., Davicioni E., Erho N., Lloyd P., Karnes R., Ross A., Schaeffer E., Griend D., Knapp S., Corey E., Feng F., Nelson P., Saatcioglu F., Knudsen K., Tammela T., Sauter G., Schlomm T., Nykter M., Visakorpi T., and Mills I., 2017, Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer, Cell Reports, 19(10): 2045-2059. https://doi.org/10.1016/j.celrep.2017.05.049 Weichert W., Röske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F., Fritzsche F., Niesporek S., Denkert C., Dietel M., Kristiansen G., and Kristiansen G., 2008, Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy, British Journal of Cancer, 98: 604-610. https://doi.org/10.1038/sj.bjc.6604199 Yang C., Zhang J.Y., Ma Y.K., Wu C.F., Cui W., and Wang L.H., 2020, Histone methyltransferase and drug resistance in cancers, Journal of Experimental and Clinical Cancer Research, 39(1): 173. https://doi.org/10.1186/s13046-020-01682-z Yang L., Jin M.L., and Jeong K.W., 2021, Histone H3K4 methyltransferases as targets for drug-resistant cancers, Biology, 10(7): 581. https://doi.org/10.3390/biology10070581
RkJQdWJsaXNoZXIy MjQ4ODYzNA==